Q2 2024 EPS Estimates for Mustang Bio, Inc. (NASDAQ:MBIO) Decreased by Analyst

Mustang Bio, Inc. (NASDAQ:MBIOFree Report) – Analysts at HC Wainwright reduced their Q2 2024 EPS estimates for Mustang Bio in a research report issued to clients and investors on Thursday, May 16th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.14) for the quarter, down from their prior forecast of ($0.13). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Mustang Bio’s current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Mustang Bio’s Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.61) EPS and FY2025 earnings at ($0.35) EPS.

Mustang Bio Trading Down 7.5 %

Shares of NASDAQ:MBIO opened at $0.31 on Monday. Mustang Bio has a 12-month low of $0.22 and a 12-month high of $8.17. The stock’s 50-day moving average price is $0.60 and its 200-day moving average price is $1.12. The stock has a market capitalization of $3.22 million, a P/E ratio of -0.07 and a beta of 1.75.

Mustang Bio (NASDAQ:MBIOGet Free Report) last issued its earnings results on Monday, March 11th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($1.68) by $0.97.

Institutional Trading of Mustang Bio

An institutional investor recently bought a new position in Mustang Bio stock. Virtu Financial LLC purchased a new stake in shares of Mustang Bio, Inc. (NASDAQ:MBIOFree Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 30,176 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.29% of Mustang Bio at the end of the most recent reporting period. 9.95% of the stock is currently owned by institutional investors.

Mustang Bio Company Profile

(Get Free Report)

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Further Reading

Earnings History and Estimates for Mustang Bio (NASDAQ:MBIO)

Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.